Moderna (MRNA) has been in focus after its recent quarter showed significant year over year revenue growth that beat market expectations, along with fresh European approvals and progress in late stage pipeline programs.

Even with the recent pullback, with the 1 month share price return down 21.82% and the 7 day share price return down 6.17%, Moderna still shows strong year to date share price momentum of 76.57% and a 1 year total shareholder return of 69.49%. However, the 3 year and 5 year total shareholder returns remain sharply lower, which keeps recent gains in the context of a much weaker long run.

If Moderna’s recent moves have you looking at where else capital could go in healthcare, this is a good time to scan for other opportunities in 41 healthcare AI stocks.

Moderna’s sharp pullback sits against a big year-to-date rebound and fresh product wins in Europe. Has most of that re-rating already happened, or does the current price still leave meaningful upside on the table as the pipeline matures?

Most Popular Narrative: 23.1% Overvalued

At a last close of $54.49 versus a narrative fair value of $44.25, the most followed Moderna narrative frames the stock as pricing in a premium and then works backward through growth and margin assumptions to justify that gap.

The dramatic expansion and advancement of Moderna's mRNA pipeline beyond COVID-19, including recent positive late-stage data and upcoming filings for flu, RSV, CMV, oncology, and rare diseases, are likely to diversify the revenue base, capitalize on the rising global burden of infectious and chronic diseases, and materially boost future top-line growth.

Regulatory momentum and robust relationships with agencies (as reflected in multiple recent FDA approvals and ongoing engagement for pipeline submissions) position the company to benefit from accelerated approval pathways, enabling faster commercialization of innovative products and unlocking earlier revenue streams.

Want to see what revenue trajectory and margin shift sit behind that fair value for Moderna? The narrative leans on aggressive growth, richer profitability, and a punchy future earnings multiple. The details show how those pieces tie together into a single valuation story.

Result: Fair Value of $44.25 (OVERVALUED)

However, Moderna’s story could still be knocked off course if COVID and RSV demand weakens further, or if regulatory scrutiny slows key vaccine launches.

Next Steps

Given the mix of optimism and caution around Moderna, this is a good moment to look through the data yourself and stress test the key assumptions. To see where that optimism is coming from, review the 1 key reward.

Looking for more investment ideas beyond Moderna?

If Moderna has sharpened your focus on where to put fresh capital next, use this moment to widen your search with a few targeted stock ideas from the Simply Wall Street Screener.

• Hunt for quality at a discount by scanning 49 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their strengths.
• Build a steadier income stream by checking out 9 dividend fortresses that offer higher yields with an emphasis on durability.
• Prioritize resilience by reviewing 85 resilient stocks with low risk scores that score well on financial strength and lower volatility so you are not caught off guard by the next swing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.